Hend Gamal
*a,
Eman Mostafa Shoeibb,
Areej Hajjajb,
Heba Elsafy Abdelaziz Abdullahbc,
Esmail H. Elramyc,
Doaa Ahmed Abd Ellahc,
Shorouk Mahmoud El-Sayedc and
Mohammad Fadl Khderc
aDepartment of Zoology, College of Science, University of Mansoura, Mansoura, Egypt. E-mail: hendooz12345@gmail.com
bDepartment of Biotechnology, College of Science, University of Mansoura, Department of Biochemistry, College of Science, University of South Valley, Department of Biochemistry, College of Science, Alexandria University, Egypt
cDepartment of Biochemistry, College of Science, University of Al Azhar, Department of Microbiology and Chemistry, College of Science, South Valley University, Biotechnology Agriculture College, University of Zagazig, Department of Zoology, College of Science, University of Al Azhar, Egypt
First published on 10th July 2025
Patients with cancer have faced exhausting physical and mental obstacles as a result of traditional treatment methods including chemotherapy and radiation therapy. In cancer, drug repurposing—the use of already-approved medications for novel therapeutic indications—has become a game-changing tactic. This method greatly lowers development costs and durations by utilizing the wealth of safety and pharmacokinetic data available for licensed medications. Large-scale databases and advanced computer techniques enable it to logically find either combinations of traditional medications or selective “non-selective” target medications. Furthermore, repurposing cancer drugs can undergo a significant and profound change thanks to genome-editing technologies like CRISPR-dCas9. It is recognized that there is yet unrealized potential of these advanced methods in further applications. Understanding the pros and cons of these technologies can provide valuable insights for clinical practice and fundamental research projects. This research will explore various innovative methods, including artificial intelligence (AI) algorithms, supervised machine learning (ML), data resources for in silico, microbial clustered regularly interspaced short palindromic repeats-dCas9 (CRISPR-dCas9) based artificial transcription factors, and combination therapy. This comprehensive guide outlines various methods for repurposing drugs, addressing effects, trials, barriers, and potential solutions to aid clinicians and researchers in maximizing efficacy and efficiency.
Drug | Pharmacological Class | Original Use | Impact of the medication on cancer-related gene regulation | CRISPR-dCas9-assisted complementary gene regulation | Cancer types |
---|---|---|---|---|---|
Aspirin | Salicylate | Pain and fever | Downregulation of the Sp family of transcription factors | Inhibition of genes for COX-enzymes | Colorectal64,65,67,70–72 |
Metformin | Oral antidiabetic | Type 2 diabetes | Blocking mTORC1 activity and turning on AMPK | Expression of AMPK | Hepatocarcinoma, breast, colorectal, and prostate66,73 |
Doxycycline | Antibiotic | Bacterial infections | Inhibition of MMP-2 and MMP-9 | Expression of TIMP-2 | Hepatocarcinoma, lung, prostate, and colorectal66,80,81 |
Nelfinavir | Antiviral | HIV treatment | Increasing DR5 expression and inhibiting AKT | Expression of SREBP-1 and ATF6 | Lung, ovary, and breast66,74 |
Lithium | Antidepressant | Major depression and bipolar disorder | Inhibition of glycogen synthase kinase 3 | Inhibition of Smad3 and TGFBIp | Prostate and colorectal66,82,83 |
Ibuprofen | NSAIDs | Pain, fever, and inflammation | Levels of Akt, p53, Bcl-2, and Bax expression | Inhibition of genes encoding COX enzymes | Colorectal and melanoma66,75,76 |
Digitoxin | Cardiac glycosides | Cardiac complications | Expression of p21 | Inhibition of HIF-1 and HIF-2 | Prostate, lung, and breast12,67,68 |
Ritonavir | Antiviral | HIV treatment | Increase in p53 expression and suppression of pRb | Expression of p21 | Ovary, breast, and pancreatic66,73 |
Mebendazole | Microbiological agent | Parasitic worm infection | Expression of pro-apoptotic Bcl-2 | Inhibition of ABL and BRAF | Colorectal, melanoma, and glioblastoma66,70–72 |
Itraconazole | Microbiological agent | Fungal infections | Blocking the activity of 14-alpha-lanosterol demethylase | Reduced activity of AKT1 | Lung and prostate66,79 |
Chlorpromazine | Antipsychotic drugs | Schizophrenia, and bipolar disorder | Expression of p21 suppression of the oncogene K-Ras | Expression of p53 | Colorectal, glioma, and leukemia66,69 |
Artesunate | Microbiological agent | Malaria | Production of pro-apoptotic proteins like caspase-3 | Inhibition of anti-apoptotic proteins and MYC oncogenes. | Lymphoma, myeloma, and hepatocarcinoma66,77–79 |
DNA | Deoxyribonucleic acid |
CSCs | Cancer stem cells |
CRISPR-dCas9 | Clustered regularly interspaced short palindromic repeats-dCas9 |
ML | Machine learning |
AI | Artificial intelligence |
PDD | Phenotypic screening drug discovery |
GWASs | Genome-wide association studies |
GB | Glioblastoma |
TP53 | Tumor suppressor gene 35 |
MMP9 | Matrix metalloprotease 9 |
CRISPR-ATFs | CRISPR-dCas9-based artificial transcription factors |
DBDs | DNA-binding domains |
ZFs | Zinc fingers |
TALEs | Transcription activator-like effectors |
sgRNA | Single guide RNA |
DTs | Decision trees |
RFs | Random forests |
SVMs | Support vector machines |
NN | Neural network |
DL | Deep learning |
RNNs | Recurrent neural networks |
CNNs | Convolutional neural networks |
GBA | Gradient boosting algorithms |
TME | Tumor microenvironment |
BC | Breast cancer |
FOLFIRI | FU/leucovorin/irinotecan |
CAPOX | Capecitabine/oxaliplatin |
NDA | New drug application |
IP | Intellectual property |
This journal is © The Royal Society of Chemistry 2025 |